GAVI Support for New Vaccine

New Typhoid Vaccine to receive GAVI Support. Governments across Africa and Asia can apply for funding to protect children against typhoid fever. Gavi, the Vaccine Alliance will support eligible countries to introduce the new typhoid conjugate vaccine into their routine immunisation schedules.

“The typhoid conjugate vaccine will not only save lives, but also bolster the fight against anti-microbial drug-resistance,” said Dr Seth Berkley CEO of Gavi, the Vaccine Alliance. “Expanding vaccine coverage will play an important role in reducing illnesses and deaths from typhoid. Gavi is looking forward to working with countries to support the introduction of this safe and effective vaccine.”

The WHO announced the prequalification of the first typhoid conjugate vaccine (TCV), Typbar-TCV, in December 2017. Earlier that month the Gavi Board approved US$ 85 million for 2019-2020 to support its introduction in developing countries. The first introductions are expected to take place in 2019.

In October 2017, WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) re-emphasised the importance of the use of typhoid vaccines in tackling the increase in anti-microbial resistance in low- and middle-income countries, as well as for the control of endemic typhoid.

Source (full article): GAVI

Featured Partner

Leave a Reply